CFTR and cystic fibrosis: Rapamycin and MK-2206, both inhibitors of PI3K/Akt/mTOR pathway, reduced the severity of CF inflammation and improved the CFTR stability in airway epithelial cells in preclinical studies (Abdulrahman et al., 2011; Reilly et al., 2017).